INT52965

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 1994
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 18
Total Number 19
Disease Relevance 8.38
Pain Relevance 1.90

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

molecular_function (TNXA) cellular_component (TNXA) biological_process (TNXA)
Anatomy Link Frequency
platelet 1
TNXA (Homo sapiens)
Pain Link Frequency Relevance Heat
anesthesia 20 99.54 Very High Very High Very High
antagonist 53 99.36 Very High Very High Very High
cva 353 99.00 Very High Very High Very High
Bioavailability 32 95.84 Very High Very High Very High
epidural 8 83.40 Quite High
cINOD 3 83.28 Quite High
Percutaneous transluminal coronary angioplasty 1 75.00 Quite High
Angina 11 72.88 Quite High
aspirin 105 62.12 Quite High
Onset of action 2 44.16 Quite Low
Disease Link Frequency Relevance Heat
Heparin-induced Thrombocytopenia 50 99.76 Very High Very High Very High
Hemorrhage 307 99.04 Very High Very High Very High
Cardiovascular Disease 2 98.24 Very High Very High Very High
Thrombosis Related Under Development 193 96.36 Very High Very High Very High
Thrombosis 155 93.92 High High
Frailty 51 93.80 High High
Arrhythmias 2 Under Development 164 92.88 High High
Pulmonary Embolism 28 92.72 High High
Stroke 174 91.60 High High
Hematoma 7 89.28 High High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The specific platelet IIb/IIIa inhibitors, hirudin, hirulog, and factor Xa inhibitors have all shown promise in animal models of restenosis, and ongoing or planned trials will define their efficacy in humans.
Negative_regulation (inhibitors) of Xa in platelet associated with cardiovascular disease
1) Confidence 0.43 Published 1994 Journal Cardiol Clin Section Abstract Doc Link 7805084 Disease Relevance 0.57 Pain Relevance 0.11
Use of neuraxial anesthesia with selective factor Xa inhibitors.
Negative_regulation (inhibitors) of Xa associated with anesthesia and cva
2) Confidence 0.36 Published 2002 Journal Am J. Orthop. Section Title Doc Link 12463580 Disease Relevance 0.19 Pain Relevance 0.60
Extreme caution is also warranted in patients treated with newer compounds as the thienopyridines, glycoprotein IIb/IIIa receptor antagonists, heparinoids, selective factor Xa inhibitors, and direct thrombin inhibitors.
Negative_regulation (inhibitors) of Xa associated with antagonist
3) Confidence 0.21 Published 2003 Journal Minerva Anestesiol Section Abstract Doc Link 12768175 Disease Relevance 0.25 Pain Relevance 0.29
Fondaparinux, a pentasaccharide, is a synthetic indirect inhibitor of Factor Xa (FXa).
Negative_regulation (inhibitor) of Xa
4) Confidence 0.18 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2879296 Disease Relevance 1.01 Pain Relevance 0.03
It is composed of sulfated glycosaminoglycans and can be used as an alternative to heparin in patients suffering from HIT.31

Factor Xa inhibitors

Negative_regulation (inhibitors) of Xa associated with heparin-induced thrombocytopenia
5) Confidence 0.13 Published 2010 Journal Vascular Health and Risk Management Section Body Doc Link PMC2879296 Disease Relevance 1.07 Pain Relevance 0.03
Factor Xa inhibitors
Negative_regulation (inhibitors) of Xa
6) Confidence 0.03 Published 2010 Journal Curr Treat Options Cardiovasc Med Section Body Doc Link PMC2860552 Disease Relevance 0.62 Pain Relevance 0.06
Other therapies discussed include oral anticoagulation, single antiplatelet therapies, oral anticoagulation plus antiplatelet treatment, direct thrombin inhibitors, and factor Xa inhibitors.



Negative_regulation (inhibitors) of Xa
7) Confidence 0.02 Published 2010 Journal Curr Treat Options Cardiovasc Med Section Abstract Doc Link PMC2860552 Disease Relevance 0.97 Pain Relevance 0.03
The discussion alluded to above on the role of Xa inhibition in the infancy of low-molecular-weight heparins could thereby be further argumued.
Negative_regulation (inhibition) of Xa
8) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994024 Disease Relevance 0.14 Pain Relevance 0.07
It was therefore of great theoretical interest when selective Xa inhibitors were identified, because it was then possible to answer the question: is it possible to obtain a good prophylactic effect by focusing on just one of the factors in the coagulation system?
Negative_regulation (inhibitors) of Xa
9) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994024 Disease Relevance 0.16 Pain Relevance 0.08
Inhibition of factor Xa (Figure 1)
Negative_regulation (Inhibition) of Xa
10) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994024 Disease Relevance 0.11 Pain Relevance 0.05
Review of fondaparinux sodium injection for the prevention of venous thromboembolism in patients undergoing surgery

The antithrombin binding sequence of heparin, a pentasaccharide, has been synthesized as fondaparinux, an indirect, selective, and reversible factor Xa inhibitor.

Negative_regulation (inhibitor) of Xa associated with cva and thrombosis related under development
11) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Title Doc Link PMC1994024 Disease Relevance 0.36 Pain Relevance 0.05
The aim of this paper is to summarize present-day knowledge on the prophylactic effect of fondaparinux, a purely synthetic selective indirect inhibitor of factor Xa, the first representative of a new class of antithrombotic substances (Cheng 2002; Hoppensteadt et al 2003; Nijkeuter and Huisman 2004).


Negative_regulation (inhibitor) of Xa
12) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994024 Disease Relevance 0.12 Pain Relevance 0.06
In the very beginning of the low-molecular-weight heparin era it was considered important to have a high factor Xa inhibitor activity which ideally should be higher than the IIa inhibitor activity, but over the years the discussion came to focus on the optimal balance between inhibiting factor Xa and factor IIa.
Negative_regulation (inhibiting) of Xa
13) Confidence 0.01 Published 2006 Journal Vascular Health and Risk Management Section Body Doc Link PMC1994024 Disease Relevance 0.17 Pain Relevance 0.08
Current therapy choices include conventional unfractionated heparin (UFH) and newer agents, in particular low molecular weight heparin (LMWH), factor Xa inhibitors and direct thrombin inhibitors.
Negative_regulation (inhibitors) of Xa
14) Confidence 0.01 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2496975 Disease Relevance 0.36 Pain Relevance 0.11
Binding of pentasaccharide to antithrombin-III induces conformational changes leading to selective and potent inhibition of factor Xa resulting in greatly reduced thrombin generation (Coussement et al 2001).
Negative_regulation (inhibition) of Xa
15) Confidence 0.01 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2496975 Disease Relevance 0.59 Pain Relevance 0.04
Pentasaccharides, such as fondaparinux, can therefore be considered as synthetic, highly selective, indirect inhibitors of factor Xa.
Negative_regulation (inhibitors) of Xa
16) Confidence 0.01 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2496975 Disease Relevance 0.49 Pain Relevance 0.05
However, more recent placebo controlled data have demonstrated benefit for use of concomitant LMWH (Simoons et al 2002; Yusuf et al 2005) and factor Xa inhibition (Yusuf et al 2006) with streptokinase.
Negative_regulation (inhibition) of Xa
17) Confidence 0.01 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2496975 Disease Relevance 0.30 Pain Relevance 0.03
The role of UFH in STEMI, particularly as an adjunct to fibrinolytic therapy, is being strongly challenged by the wealth of data surrounding newer anticoagulants including LMWH, factor Xa inhibitors and direct thrombin inhibitors.
Negative_regulation (inhibitors) of Xa
18) Confidence 0.01 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2496975 Disease Relevance 0.49 Pain Relevance 0
The ratio of inhibition of factor Xa:IIa varies between agents (for enoxaparin the ratio is 3:1) (Armstrong 1997).
Negative_regulation (inhibition) of Xa
19) Confidence 0.01 Published 2008 Journal Vascular Health and Risk Management Section Body Doc Link PMC2496975 Disease Relevance 0.42 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox